Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x100px
Collaboration › Details

AstraZeneca–Eccogene: GLP-1 receptor agonist, 202311– license ww excl $185m upfront + $1.825b milestones + royalties for ECC5004


Period Period 2023-11-09
Region Region ALL
Organisations Partner, 1st AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
  Partner, 2nd Eccogene (CN)
Products Product ECC5005 (Eccogene / AstraZeneca)
  Product 2 obesity drug
Document Source AstraZeneca plc. (11/9/23). "Press Release: AstraZeneca Licenses Novel Agent for the Treatment of Cardiometabolic Conditions and Obesity [This press release is intended for investors and business / science media]".

Record changed: 2024-02-05


Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for AstraZeneca (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x300px

» top